Akshat Saxena1, Terence C Chua, Francis C Chu, David L Morris. 1. Department of Surgery, Hepatobiliary and Surgical Oncology Unit, University of New South Wales, St. George Hospital, Level 3 Pitney Building, Short St., Kogarah, New South Wales 2217, Sydney, Australia.
Abstract
BACKGROUND: Hilar cholangiocarcinoma (HC) is invariably fatal without surgical intervention. The primary aim of the current study was to report overall survival and recurrence-free survival outcomes after surgical resection of HC. METHODS: Between December 1992 and December 2009, 85 patients were evaluated; of these, 42 patients underwent potentially curative surgery. These patients are the principal subjects of this study. Patients were assessed monthly for the first 3 months and then at 6-month intervals after treatment. Recurrence-free survival and overall survival were determined; 18 clinicopathologic and treatment-related factors associated with recurrence-free survival and overall survival were evaluated through univariate and multivariate analyses. RESULTS: No patient was lost to follow-up evaluation. The median follow-up period was 20 months (range, 0-106 mo). The median recurrence-free survival and overall survival after resection was 15 and 28 months, respectively. The 5-year survival rate was 24%. Two factors were associated with overall survival: histologic grade (P = .002) and margin status (P = .033). Only histologic grade (P = .029) was associated with recurrence-free survival. CONCLUSIONS: Surgical resection is an efficacious treatment for HC. Patient selection based on identified prognostic factors can improve treatment outcomes.
BACKGROUND:Hilar cholangiocarcinoma (HC) is invariably fatal without surgical intervention. The primary aim of the current study was to report overall survival and recurrence-free survival outcomes after surgical resection of HC. METHODS: Between December 1992 and December 2009, 85 patients were evaluated; of these, 42 patients underwent potentially curative surgery. These patients are the principal subjects of this study. Patients were assessed monthly for the first 3 months and then at 6-month intervals after treatment. Recurrence-free survival and overall survival were determined; 18 clinicopathologic and treatment-related factors associated with recurrence-free survival and overall survival were evaluated through univariate and multivariate analyses. RESULTS: No patient was lost to follow-up evaluation. The median follow-up period was 20 months (range, 0-106 mo). The median recurrence-free survival and overall survival after resection was 15 and 28 months, respectively. The 5-year survival rate was 24%. Two factors were associated with overall survival: histologic grade (P = .002) and margin status (P = .033). Only histologic grade (P = .029) was associated with recurrence-free survival. CONCLUSIONS: Surgical resection is an efficacious treatment for HC. Patient selection based on identified prognostic factors can improve treatment outcomes.
Authors: Jean Marc Regimbeau; David Fuks; Patrick Pessaux; Philippe Bachellier; Denis Chatelain; Momar Diouf; Artigas Raventos; Georges Mantion; Jean-Francois Gigot; Laurence Chiche; Gerard Pascal; Daniel Azoulay; Alexis Laurent; Christian Letoublon; Emmanuel Boleslawski; Michel Rivoire; Jean-Yves Mabrut; Mustapha Adham; Yves-Patrice Le Treut; Jean-Robert Delpero; Francis Navarro; Ahmet Ayav; Karim Boudjema; Gennaro Nuzzo; Michel Scotte; Olivier Farges Journal: HPB (Oxford) Date: 2014-07-03 Impact factor: 3.647
Authors: Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik Journal: Langenbecks Arch Surg Date: 2014-06-25 Impact factor: 3.445
Authors: Jin Hong Lim; Gi Hong Choi; Sung Hoon Choi; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee Journal: World J Surg Date: 2013-04 Impact factor: 3.352